If Padzur retires, he would become one of several high-ranking FDA officials who left the agency in 2025.
ATUM’s Leap-In platform enables AGC Biologics to offer various cell line development solutions for customers.
The partnership combines Citizen Health’s AI-based patient insights with UCB’s drug development expertise to improve outcomes.
Patient advocacy and industry bodies welcomed the bill’s backing, though it will now need to be passed in the Senate.
As part of the 0% tariff deal, the NHS will pay 25% more for innovative medicines.
